KR20010023313A - Ｇａｂａ 뇌 수용체 리간드로서의 치환된4-옥소-나프티리딘-3-카르복스아미드 - Google Patents

Ｇａｂａ 뇌 수용체 리간드로서의 치환된4-옥소-나프티리딘-3-카르복스아미드 Download PDF

Info

Publication number
KR20010023313A
KR20010023313A KR1020007001948A KR20007001948A KR20010023313A KR 20010023313 A KR20010023313 A KR 20010023313A KR 1020007001948 A KR1020007001948 A KR 1020007001948A KR 20007001948 A KR20007001948 A KR 20007001948A KR 20010023313 A KR20010023313 A KR 20010023313A
Authority
KR
South Korea
Prior art keywords
oxo
naphthyridine
carboxamide
tetrahydro
compound according
Prior art date
Application number
KR1020007001948A
Other languages
English (en)
Korean (ko)
Inventor
파멜라 알버
로버트 더블유. 데시몬
강 리우
Original Assignee
해피 페너 ; 해리 에이치. 페너 2세
뉴로젠 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 해피 페너 ; 해리 에이치. 페너 2세, 뉴로젠 코포레이션 filed Critical 해피 페너 ; 해리 에이치. 페너 2세
Publication of KR20010023313A publication Critical patent/KR20010023313A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020007001948A 1997-08-25 1998-08-24 Ｇａｂａ 뇌 수용체 리간드로서의 치환된4-옥소-나프티리딘-3-카르복스아미드 KR20010023313A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91818097A 1997-08-25 1997-08-25
US08/918,180 1997-08-25
PCT/US1998/017513 WO1999010347A1 (en) 1997-08-25 1998-08-24 Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands

Publications (1)

Publication Number Publication Date
KR20010023313A true KR20010023313A (ko) 2001-03-26

Family

ID=25439933

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007001948A KR20010023313A (ko) 1997-08-25 1998-08-24 Ｇａｂａ 뇌 수용체 리간드로서의 치환된4-옥소-나프티리딘-3-카르복스아미드

Country Status (24)

Country Link
EP (1) EP1007526A1 (no)
JP (1) JP2001514181A (no)
KR (1) KR20010023313A (no)
CN (1) CN1268136A (no)
AP (1) AP2000001742A0 (no)
AU (1) AU753800B2 (no)
BG (1) BG104192A (no)
BR (1) BR9811362A (no)
CA (1) CA2301599C (no)
EG (1) EG21717A (no)
HU (1) HUP0003258A3 (no)
IL (1) IL134291A0 (no)
IS (1) IS5382A (no)
LV (1) LV12539B (no)
NO (1) NO20000822L (no)
NZ (1) NZ502548A (no)
OA (1) OA11293A (no)
PE (1) PE130999A1 (no)
PL (1) PL338783A1 (no)
SI (1) SI20270A (no)
SK (1) SK2162000A3 (no)
TW (1) TW574221B (no)
WO (1) WO1999010347A1 (no)
YU (1) YU10500A (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0010308A (pt) * 1999-05-06 2002-01-08 Neurogen Corp Composto, composição farmacêutica, uso de um composto, e, métodos para o tratamento de uma doença ou distúrbio associados com o agonismo patogênico, agonismo inverso ou antagonismo do receptor de gabaa, para localizar receptores de gabaa em uma amostra de tecido, para inibir a ligação de um composto de benzodiazepina a um receptor de gabaa e para alterar a atividade da transdução de sinal dos receptores de gabaa, e, composição farmacêutica embalada
WO2000071528A1 (en) * 1999-05-25 2000-11-30 Neurogen Corporation 4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands
US6562822B2 (en) 2000-07-12 2003-05-13 Pharmacia & Upjohn Company Heterocyle carboxamides as antiviral agents
US6730682B2 (en) 2000-07-12 2004-05-04 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
AU1152702A (en) 2000-10-12 2002-04-22 Merck & Co Inc Aza- and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors
US6919351B2 (en) 2000-10-12 2005-07-19 Merck & Co., Inc. Aza-and polyaza-naphthalenyl-carboxamides useful as HIV integrase inhibitors
ES2274913T3 (es) 2000-10-12 2007-06-01 MERCK & CO., INC. Aza y poliaza-naftalenil carboxamidas utiles como inhibidores de vih integrada.
US20020151591A1 (en) * 2000-10-17 2002-10-17 Anabella Villalobos Combination use of acetylcholinesterase inhibitors and GABAa inverse agonists for the treatment of cognitive disorders
HUP0303448A3 (en) * 2001-03-01 2005-05-30 Pfizer Prod Inc Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders
AR036256A1 (es) 2001-08-17 2004-08-25 Merck & Co Inc Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento
DE60315796T2 (de) 2002-01-17 2008-06-05 Merck & Co., Inc. Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen
US7323460B2 (en) 2002-03-15 2008-01-29 Merck & Co., Inc. N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as HIV integrase inhibitors
WO2004106336A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Process for the preparation and purification of 1,5-naphthyridine-3-carboxyamides
WO2004106334A2 (en) * 2003-05-28 2004-12-09 Pfizer Products Inc. Process for the preparation of 1,5-naphthyridine-3-carboxy amides by direct ester amidation
PT2074123E (pt) * 2006-10-16 2013-01-22 Bionomics Ltd Novos compostos ansiolíticos
HUE032743T2 (en) * 2006-11-22 2017-10-30 Clinical Res Ass Llc A method for treating Down syndrome, fragilis X syndrome and autism

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR204162A1 (es) * 1972-05-08 1975-11-28 Yamanouchi Pharma Co Ltd Proceso para la preparacion de derivados de ampicilina
GB1433774A (en) * 1973-02-26 1976-04-28 Allen & Hanburys Ltd Heterocyclic compounds apparatus for conveying articles
US4374138A (en) * 1981-11-13 1983-02-15 Warner-Lambert Company Antibacterial amide compounds, compositions, and methods of use
DD295360A5 (de) * 1987-07-03 1991-10-31 Akad Wissenschaften Verfahren zur Herstellung von aktivierten Carbonsäureestern
DD279875A1 (de) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun Verfahren zur herstellung von aktivierten carbonsaeureestern
DD279887A1 (de) * 1987-07-03 1990-06-20 Inst Pharmakologische Forschun Verfahren zur herstellung von d-alpha-(4(1h)-1,5-naphthyridon-3-carboxamido)-benzylpenicillin und anderen beta-lactamantibiotika
JPS6461461A (en) * 1987-09-01 1989-03-08 Otsuka Pharma Co Ltd Benzohetero ring derivative

Also Published As

Publication number Publication date
LV12539A (en) 2000-10-20
LV12539B (en) 2001-01-20
HUP0003258A2 (en) 2001-03-28
JP2001514181A (ja) 2001-09-11
TW574221B (en) 2004-02-01
IS5382A (is) 2000-02-22
CA2301599A1 (en) 1999-03-04
EP1007526A1 (en) 2000-06-14
PE130999A1 (es) 1999-12-16
NO20000822L (no) 2000-04-13
CN1268136A (zh) 2000-09-27
NO20000822D0 (no) 2000-02-18
OA11293A (en) 2002-11-19
NZ502548A (en) 2002-06-28
YU10500A (sh) 2002-10-18
AU9117398A (en) 1999-03-16
AP2000001742A0 (en) 2000-02-24
EG21717A (en) 2002-02-27
AU753800B2 (en) 2002-10-31
BG104192A (en) 2001-05-31
PL338783A1 (en) 2000-11-20
CA2301599C (en) 2003-03-25
SI20270A (sl) 2000-12-31
SK2162000A3 (en) 2001-03-12
HUP0003258A3 (en) 2001-05-28
BR9811362A (pt) 2000-08-22
IL134291A0 (en) 2001-04-30
WO1999010347A1 (en) 1999-03-04

Similar Documents

Publication Publication Date Title
US6399604B1 (en) Substituted 4-OXO-napthyridine-3-carboxamides; GABA brain receptor ligands
US6103903A (en) 4-(4-piperidylmethyhlamino) substituted heteroaryl fused pyridines: GABA brain receptor ligands
US6423711B1 (en) Heterocyclic amino substituted heteroaryl fused pyridines; GABA brain receptor ligands
KR20010023313A (ko) Ｇａｂａ 뇌 수용체 리간드로서의 치환된4-옥소-나프티리딘-3-카르복스아미드
US6156898A (en) Substituted 1,4-dihydro-4-oxonicotinic carboxamides; GABA brain receptor ligands
DE60214990T2 (de) Benzolsulfonsäureester-indol-5-yl als 5-ht6 rezeptor-antagonisten
US6177569B1 (en) Oxo-pyridoimidazole-carboxamides: GABA brain receptor ligands
US5908932A (en) Certain pyrroloquinolinones; a new class of GABA brain receptor
US6194427B1 (en) Substituted cycloalkyl-4-Oxonicotinic carboxamides; gaba brain receptor ligands
US6297252B1 (en) Imidazo[1,5-c]quinazolines; A new class of GABA brain receptor ligands
DE102004047272A1 (de) Inhibitoren der löslichen Adenylatzyklase
EP2036906A1 (de) Azaindole als Inhibitoren der löslichen Adenylatzyklase
EP1107966B1 (en) Oxo-pyridoimidazole-carboxamides: gaba brain receptor ligands
MXPA00001598A (en) Substituted 4-oxo-napthyridine-3-carboxamides as gaba brain receptor ligands
MXPA01001991A (en) Oxo-pyridoimidazole-carboxamides:gaba brain receptor ligands
MXPA00008364A (en) Substituted cycloalkyl-4-oxonicotinic carboxamides;gaba brain receptor ligands

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid